The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol

[1]  A. Shoemark,et al.  The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. , 2019, The Lancet. Respiratory medicine.

[2]  W. Boersma,et al.  Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. , 2019, The Lancet. Respiratory medicine.

[3]  W. Boersma,et al.  Aetiology and disease severity are among the determinants of quality of life in bronchiectasis , 2019, The clinical respiratory journal.

[4]  A. O'donnell,et al.  Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. , 2019, The Lancet. Respiratory medicine.

[5]  C. Castellani,et al.  ECFS best practice guidelines: the 2018 revision. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  J. Elborn,et al.  RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.

[7]  Katrin Roth,et al.  RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.

[8]  T. Welte,et al.  European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.

[9]  J. Laffey,et al.  Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. , 2016, The Lancet. Respiratory medicine.

[10]  A. O'donnell,et al.  Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores , 2014, Thorax.

[11]  W. Boersma,et al.  Validation of a visual analogue score (LRTI‐VAS) in non‐CF bronchiectasis , 2014, The clinical respiratory journal.

[12]  E. Stovold,et al.  Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review , 2014, European Respiratory Journal.

[13]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[14]  Edward T Naureckas,et al.  Non-cystic fibrosis bronchiectasis. , 2013, American journal of respiratory and critical care medicine.

[15]  A. Hill,et al.  Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. , 2013, Molecular immunology.

[16]  A. Smyth,et al.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. , 2013, The Cochrane database of systematic reviews.

[17]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[18]  A. Hill,et al.  Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. , 2012, American journal of respiratory and critical care medicine.

[19]  A. Hill,et al.  Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis , 2009, European Respiratory Journal.

[20]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[21]  F. Scaglione,et al.  Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection , 2006, Expert review of anti-infective therapy.

[22]  E. Shore,et al.  A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. , 2005, Chest.

[23]  P. Suñé,et al.  Inhaled Tobramycin in Non—Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas Aeruginosa , 2005, The Annals of pharmacotherapy.

[24]  J. Ioannidis,et al.  Extended-interval aminoglycoside administration for children: a meta-analysis. , 2004, Pediatrics.

[25]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[26]  D. Nicolau,et al.  Extended interval aminoglycoside dosing: from concept to clinic. , 2002, International journal of antimicrobial agents.

[27]  G. Sampol,et al.  Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. , 1999, Respiratory medicine.

[28]  T. Hazinski.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. , 1999, The Journal of pediatrics.

[29]  M S Pepe,et al.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.

[30]  F. Ratjen,et al.  Placebo‐controlled, double‐blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis , 1998, Pediatric pulmonology.

[31]  M. Nahata,et al.  Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. , 1997, Chest.

[32]  R. Hatala,et al.  Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  R. Wilson,et al.  Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. , 1994, The Journal of antimicrobial chemotherapy.

[34]  D. Signorini,et al.  Sample size for Poisson regression , 1991 .

[35]  A. Hill,et al.  Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. , 2013, QJM : monthly journal of the Association of Physicians.

[36]  A. Hill,et al.  Non-cystic fibrosis bronchiectasis. , 2009, Clinical medicine.

[37]  Kenneth Meyer,et al.  Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[38]  P. Cole.  Inflammation: a two-edged sword--the model of bronchiectasis. , 1986, European journal of respiratory diseases. Supplement.